Abstract
Traditional Chinese medicine is an important component of the health care system in Chinese medical treatment and public health. Rare disease drugs in difficult miscellaneous diseases in traditional Chinese medicine have similar characteristics with the rare disease drugs (orphan drugs) in European and American countries, which both are characterized by individualized medical treatment. The two are different in the development thought. Treatment of difficult miscellaneous diseases in the traditional Chinese medicine is based on the theoretical system of drug incompatibility, whereas orphan drugs in European and American countries lay particular stress on the gene therapy in molecular biology. Adoption of positive incentive policy and excavating folk remedy in the traditional Chinese medicine will promote the market position of the traditional Chinese medicine in the field of international rare disease drugs.
Highlights
Protection of Patent System to the Traditional Chinese MedicineInternational Patent Classification (IPC) is a unique instrument that is compiled for classification of patent technology based on “International Patent classification Agreement/Strasbourg agreement” signed in 1971
Traditional Chinese medicine is an important component of the health care system in Chinese medical treatment and public health
Rare disease drugs in difficult miscellaneous diseases in traditional Chinese medicine have similar characteristics with the rare disease drugs in European and American countries, which both are characterized by individualized medical treatment
Summary
International Patent Classification (IPC) is a unique instrument that is compiled for classification of patent technology based on “International Patent classification Agreement/Strasbourg agreement” signed in 1971. Rare disease drugs in the traditional Chinese medicine come from natural flora and fauna and the production costs of drugs are easy to take under control, which seems especially important for the governmental incentive policy at a research and development stage. It is quite necessary for the government to take sentinel procurement policy, government capital investment, preferential tax guiding policy to improve enthusiasm of research, development and production of drugs for difficult miscellaneous diseases in the traditional Chinese medicine. The government realizes national and regional medical care insurance coverage ratio to enhance the overall level of the national medical care insurance by means of constructing a price negotiation mechanism of rare disease drugs of the traditional Chinese medicine, which includes either government capital investment at an early stage or sentinel procurement at a later stage
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
